Gemtuzumab ozogamicin – Uses, Dosage, Side Effects, Interation Gemtuzumab ozogamicin is a monoclonal anti-CD33 antibody used to treat CD33-positive acute myeloid leukemia. Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody that is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. catechesis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles of calicheamicin per mole of antibody. The antibody is specifically directed against the CD33 antigen present on leukemic myeloblasts in most patients with acute myeloid leukemia (AML). By binding to the CD33 antigen on tumors, the cytotoxic agent blocks the growth of cancerous cells and causes cell death. Marketing approval of gemtuzumab ozogamicin was granted on May 17, 2000, by FDA as a treatment for patients with CD33-positive AML in first relapse who are 60 years of age or older and who are not considered candidates for cytotoxic chemotherapy [rx]. However, it was voluntarily withdrawn from the market in 2010 due to safety concerns, increased patient deaths, and insufficient evidence of clinical benefit during confirmatory trials [rx]. On September 1, 2017, gemtuzumab ozogamicin was again approved for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia but with a lower dosing regimen and a different schedule in combination with chemotherapy or on its own [rx]. It is also indicated for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial treatment (refractory) [rx]. Mechanism of action Mylotarg is directed against the CD33 antigen expressed by hematopoietic cells. Binding of the anti-CD33 antibody portion of Mylotarg with the CD33 antigen results in the formation of a complex that is internalized. Upon internalization, the calicheamicin derivative is released inside the lysosomes of the myeloid cell. The released calicheamicin derivative binds to DNA in the minor groove resulting in site-specific DNA double-strand breaks via the formation of a p-benzene diradical 4. Eventually, cell death is induced. Used for the treatment of acute myeloid leukemia (AML), Mylotarg binds to the CD33 antigen, which is expressed on the surface of leukemic cells in more than 80% of patients with AML. The CD33 antigen is not expressed on pluripotent hematopoietic stem cells or nonhematopoietic cells. This gives Mylotarg the selectivity needed to target leukemic cells. or Gemtuzumab ozogamicin is a CD33-directed antibody-drug conjugate (ADC). The antibody portion (hP67.6) recognizes human CD33 antigen. The small molecule, N-acetyl gamma calicheamicin, is a cytotoxic agent that is covalently attached to the antibody via a linker. Nonclinical data suggest that the anticancer activity of gemtuzumab ozogamicin is due to the binding of the ADC to CD33-expressing tumor cells, followed by internalization of the ADC-CD33 complex, and the intracellular release of N-acetyl gamma calicheamicin dimethyl hydrazide via hydrolytic cleavage of the linker. Activation of N-acetyl gamma calicheamicin dimethyl hydrazide induces double-strand DNA breaks, subsequently inducing cell cycle arrest and apoptotic cell death. Indications Indicated for the treatment of patients with CD33-positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for other cytotoxic chemotherapy. Indicated for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial treatment (refractory). Acute Myeloid Leukemia (AML) Refractory Acute Myeloid Leukemia (AML) Relapsed Acute Myelogenous Leukemia (AML) Use in Cancer Gemtuzumab ozogamicin is approved to treat: Acute myeloid leukemia that is CD33 positive. It is used in adults and children aged 1 month and older with the newly-diagnosed diseases. It is used in adults and children aged 2 years and older whose disease has relapsed or is refractory (does not respond to treatment). Gemtuzumab ozogamicin is also being studied in the treatment of other types of cancer. Contraindications low amount of magnesium in the blood low amount of calcium in the blood low amount of potassium in the blood decreased blood platelets low levels of a type of white blood cell called neutrophils abnormal EKG with QT changes from birth hepatic veno-occlusive disease, a type of liver disease liver problems pregnancy a patient who is producing milk and breastfeeding Dosage Strengths: 4.5 mg Acute Myeloid Leukemia Newly diagnosed CD33-positive acute myeloid leukemia (AML): COMBINATION REGIMEN (therapy consists of 1 induction cycle and 2 consolidation cycles in combination with chemotherapy): Induction: 3 mg/m2 (maximum 4.5 mg/dose) IV over 2 hours on Days 1, 4, and 7 in combination with daunorubicin and cytarabine (for patients who require a second induction cycle, gemtuzumab is NOT given during the second induction cycle) Consolidation (2 cycles): 3 mg/m2 (maximum 4.5 mg/dose) IV over 2 hours on Day 1 in combination with daunorubicin and cytarabine Newly diagnosed CD33-positive acute myeloid leukemia (AML): SINGLE AGENT REGIMEN (MONOTHERAPY) (therapy consists of 1 induction cycle and up to 8 continuation cycles): Induction: 6 mg/m2 IV over 2 hours on Day 1 and 3 mg/m2 IV on Day 8 Continuation: 2 mg/m2 IV over 2 hours on Day 1 every 4 weeks Relapsed or Refractory CD33-positive AML: SINGLE-AGENT REGIMEN (MONOTHERAPY): 3 mg/m2 (maximum 4.5 mg/dose) IV over 2 hours on Days 1, 4, and 7 Treatment in the relapsed or refractory setting consists of a single course of gemtuzumab. Premedicate with acetaminophen 650 mg orally and diphenhydramine 50 mg orally or IV one hour prior to infusion, and methylprednisolone (or equivalent) 1 mg/kg orally or IV within 30 minutes prior to infusion. Repeat the same dose of methylprednisolone (or equivalent) for any sign of an infusion reaction (e.g., fever, chills, hypotension, dyspnea) during the infusion or within 4 hours of the infusion. Monitor vital signs during infusion and for 4 hours following infusion. For patients with hyperleukocytosis (leukocyte count greater than or equal to 30 Gi/L), cytoreduction is recommended prior to the administration of this drug. For newly diagnosed CD33-positive acute myeloid leukemia (AML) For relapsed or refractory CD33-positive AML Acute Myeloid Leukemia Newly Diagnosed De Novo CD33-positive AML (Combination Regimen): ONE MONTH AND OLDER: Body surface area (BSA) less than 0.6 m2: 0.1 mg/kg IV over 2 hours BSA 0.6 m2 or greater: 0.3 mg/m2 IV over 2 hours INDUCTION 1: For Induction 1, gemtuzumab is given once in combination with standard chemotherapy; no gemtuzumab is given in the second induction cycle. INTENSIFICATION: No gemtuzumab is given in the first or third intensification cycles; for Intensification 2, gemtuzumab is given once in combination with standard chemotherapy; consider the risks and potential benefits before giving gemtuzumab during Intensification 2. Relapsed or Refractory CD33-positive AML: SINGLE-AGENT REGIMEN (MONOTHERAPY): 2 YEARS AND OLDER: 3 mg/m2 (maximum 4.5 mg/dose) IV over 2 hours on Days 1, 4, and 7 Treatment in the relapsed or refractory setting consists of a single course of gemtuzumab. Premedicate children 1 month and older with acetaminophen 15 mg/kg (maximum of 650 mg) orally and diphenhydramine 1 mg/kg (maximum of 50 mg) orally or IV within 1 hour of infusion, and methylprednisolone 1 mg/kg orally or IV within 30 minutes of infusion. Additional doses of acetaminophen and diphenhydramine may be administered every 4 hours if needed. Repeat with the same dose of methylprednisolone (or equivalent) for an infusion reaction (e.g., fever, chills, hypotension, dyspnea) during the infusion or within 4 hours of the infusion. Monitor vital signs during infusion and for 4 hours following infusion. For patients with hyperleukocytosis (leukocyte count greater than or equal to 30 Gi/L), cytoreduction is recommended prior to the administration of this drug. For the treatment of newly diagnosed CD33-positive acute myeloid leukemia in pediatric patients 1 month and older For relapsed or refractory CD33-positive acute myeloid leukemia (AML) in pediatric patients 2 years and older Dose Adjustments FOR PATIENTS RECEIVING GEMTUZUMAB IN COMBINATION THERAPY: PERSISTENT THROMBOCYTOPENIA: ADULTS: If platelet count does not recover to greater than or equal to 100 Gi/L within 14 days following the planned start date of the consolidation cycle (14 days after hematologic recovery following the previous cycle), discontinue gemtuzumab (do not administer gemtuzumab in the consolidation cycles). PEDIATRICS: Patients should have a platelet count of 75 Gi/L before the next cycle (induction or intensification). PERSISTENT NEUTROPENIA: ADULTS: If the neutrophil count does not recover to greater than 0.5 Gi/L within 14 days following the planned start date of the consolidation cycle (14 days after hematologic recovery following the previous cycle), discontinue gemtuzumab (do not administer gemtuzumab in the consolidation cycles). PEDIATRICS: Patients should have a neutrophil count of 1 Gi/L before the next cycle (induction or intensification). FOR ALL PATIENTS RECEIVING GEMTUZUMAB (MONOTHERAPY OR COMBINATION THERAPY: VENO-OCCLUSIVE LIVER DISEASE (VOD): Manage hepatic toxicity by dose interruption or discontinuation of therapy. In patients who experience VOD, discontinue therapy and treatment according to standard medical practice. INFUSION-RELATED REACTIONS: Interrupt the infusion and manage medically. Administer acetaminophen, diphenhydramine, and/or methylprednisolone, if needed. Provide supportive care as needed. For mild, moderate, or severe infusion-related reactions, once symptoms resolve, consider resuming the infusion at no more than one-half the rate at which the reaction occurred. Repeat the procedure in the event of a recurrence of symptoms. Permanently discontinue therapy upon the occurrence of a severe infusion reaction or for any life-threatening infusion reaction. OTHER SEVERE OR LIFE-THREATENING NONHEMATOLOGIC TOXICITIES: Delay therapy until recovery to a severity of no more than mild. Omit scheduled dose if delayed more than 2 days between sequential infusions. Administration advice: Use an in-line 0.2-micron polyethersulfone (PES) filter for infusion. Protect the IV bag from light using a light-blocking cover during the infusion. The infusion line does not need to be protected from light. Infuse the diluted solution over 2 hours. Side Effects The Most Common rash diarrhea constipation nausea vomiting headache pain pain, swelling, or sores in mouth or throat unusual or severe bleeding or bruising cough, shortness of breath, or difficulty breathing fast heartbeat fever, chills, sore throat, or other signs of infection More common Bleeding gums blood in the urine or stools blurred vision bone pain chest pain chills confusion cough coughing up blood decreased urine output difficulty in breathing or swallowing dizziness, lightheadedness, or fainting dry mouth fast or irregular heartbeat fever flushed, dry skin fruit-like breath odor headache hoarseness increased hunger increased menstrual flow or vaginal bleeding increased thirst increased urination irregular heartbeat loss of appetite loss of consciousness lower back or side pain mood changes muscle pain or cramps nausea nosebleeds numbness or tingling in the hands, feet, or lips painful or difficult urination paralysis pinpoint red spots on the skin prolonged bleeding from cuts rapid, shallow breathing rash red or black, tarry stools red or dark brown urine seizures sore throat stomach pain and bloating sweating swelling of the face, ankles, or hands tightness in the chest unexplained weight loss unusual bleeding or bruising unusual tiredness or weakness vomiting Rare Blue lips and fingernails coughing that sometimes produces a pink frothy sputum difficult, fast, noisy breathing fast, pounding, or irregular heartbeat or pulse increased sweating pale skin ulcers, sores, or white spots in the mouth Stomach cramps watery or bloody diarrhea Drug Interactions DRUG INTERACTION Abatacept The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Abatacept. Abciximab The risk or severity of bleeding can be increased when Abciximab is combined with Gemtuzumab ozogamicin. Acenocoumarol The risk or severity of bleeding can be increased when Acenocoumarol is combined with Gemtuzumab ozogamicin. Acetylsalicylic acid The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Gemtuzumab ozogamicin. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Gemtuzumab ozogamicin. Adenovirus type The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Gemtuzumab ozogamicin. Aducanumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Aducanumab. Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Gemtuzumab ozogamicin. Alefacept The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Alefacept. Alemtuzumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Alemtuzumab. Alirocumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Alirocumab. Allogeneic The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Gemtuzumab ozogamicin. Allopurinol The risk or severity of adverse effects can be increased when Allopurinol is combined with Gemtuzumab ozogamicin. Alteplase The risk or severity of bleeding can be increased when Alteplase is combined with Gemtuzumab ozogamicin. Altretamine The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Altretamine. Amivantamab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Amivantamab. Amsacrine The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Amsacrine. Anagrelide The risk or severity of bleeding can be increased when Anagrelide is combined with Gemtuzumab ozogamicin. Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Gemtuzumab ozogamicin. Ancrod The risk or severity of bleeding can be increased when Ancrod is combined with Gemtuzumab ozogamicin. Anifrolumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Anifrolumab. Anistreplase The risk or severity of bleeding can be increased when Anistreplase is combined with Gemtuzumab ozogamicin. Ansuvimab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ansuvimab. Anthrax immune The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Gemtuzumab ozogamicin. Anthrax vaccine The risk or severity of infection can be increased when Anthrax vaccine is combined with Gemtuzumab ozogamicin. Antilymphocyte The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Antilymphocyte immunoglobulin (horse). Antithrombin Alfa The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Gemtuzumab ozogamicin. Antithrombin The risk or severity of bleeding can be increased when Antithrombin III human is combined with Gemtuzumab ozogamicin. Antithymocyte The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Antithymocyte immunoglobulin (rabbit). Apixaban The risk or severity of bleeding can be increased when Apixaban is combined with Gemtuzumab ozogamicin. Apremilast The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Apremilast. Ardeparin The risk or severity of bleeding can be increased when Ardeparin is combined with Gemtuzumab ozogamicin. Argatroban The risk or severity of bleeding can be increased when Argatroban is combined with Gemtuzumab ozogamicin. Arsenic trioxide The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Arsenic trioxide. Articaine The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Articaine. Asfotase alfa The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Asfotase alfa. ACOVID-19 Vaccine The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Gemtuzumab ozogamicin. Atezolizumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Atezolizumab. Atoltivimab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Atoltivimab. Avelumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Avelumab. Azacitidine The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Azacitidine. Azathioprine The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Azathioprine. Bacillus The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Gemtuzumab ozogamicin. Bacillus antigen The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Gemtuzumab ozogamicin. Bacillus calmette The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Gemtuzumab ozogamicin. Bamlanivimab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bamlanivimab. Baricitinib The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Baricitinib. Basiliximab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Basiliximab. BCG vaccine The risk or severity of infection can be increased when BCG vaccine is combined with Gemtuzumab ozogamicin. Beclomethasone The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Beclomethasone dipropionate. Belantamab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Belantamab mafodotin. Belatacept The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Belatacept. Belimumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Belimumab. Belinostat The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Belinostat. Belumosudil The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Belumosudil. Bemiparin The risk or severity of bleeding can be increased when Bemiparin is combined with Gemtuzumab ozogamicin. Bendamustine The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bendamustine. Bendroflumethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Gemtuzumab ozogamicin. Benralizumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Benralizumab. Benzocaine The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Benzocaine. Benzthiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Gemtuzumab ozogamicin. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Benzyl alcohol. Besilesomab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Besilesomab. Betamethasone The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Betamethasone. Betrixaban The risk or severity of bleeding can be increased when Betrixaban is combined with Gemtuzumab ozogamicin. Bevacizumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bevacizumab. Bexarotene The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bexarotene. Bezlotoxumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bezlotoxumab. Bimekizumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bimekizumab. Bivalirudin The risk or severity of bleeding can be increased when Bivalirudin is combined with Gemtuzumab ozogamicin. Bleomycin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bleomycin. Blinatumomab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Blinatumomab. Bordetella The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin. Bortezomib The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bortezomib. Bosutinib The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bosutinib. Brentuximab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Brentuximab vedotin. Brodalumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Brodalumab. Brolucizumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Brolucizumab. Budesonide The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Budesonide. Bupivacaine The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Bupivacaine. Burosumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Burosumab. Busulfan The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Busulfan. Butacaine The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Butacaine. Butamben The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Butamben. Cabazitaxel The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cabazitaxel. Canakinumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Canakinumab. Cangrelor The risk or severity of bleeding can be increased when Cangrelor is combined with Gemtuzumab ozogamicin. Capecitabine The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Capecitabine. Caplacizumab The risk or severity of bleeding can be increased when Caplacizumab is combined with Gemtuzumab ozogamicin. Capromab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Capromab pendetide. Capsaicin The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Capsaicin. Carbamazepine The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Carbamazepine. Carboplatin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Carboplatin. Carfilzomib The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Carfilzomib. Carmustine The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Carmustine. Casirivimab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Casirivimab. Catumaxomab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Catumaxomab. Cemiplimab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cemiplimab. Certolizumab pegol The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Certolizumab pegol. Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Gemtuzumab ozogamicin. Chlorambucil The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Chlorambucil. Chloramphenicol The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Chloramphenicol. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Chloroprocaine. Chlorothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Gemtuzumab ozogamicin. Ciclesonide The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ciclesonide. Cilgavimab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cilgavimab. Cilostazol The risk or severity of bleeding can be increased when Cilostazol is combined with Gemtuzumab ozogamicin. Cinchocaine The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Cinchocaine. Cisplatin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cisplatin. Cladribine The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cladribine. Clobetasol The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Clobetasol propionate. Clofarabine The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Clofarabine. Clopidogrel The risk or severity of bleeding can be increased when Clopidogrel is combined with Gemtuzumab ozogamicin. Clostridium The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin. Clozapine The risk or severity of neutropenia can be increased when Gemtuzumab ozogamicin is combined with Clozapine. Cocaine The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Cocaine. Cestrogens Conjugated estrogens may increase the thrombogenic activities of Gemtuzumab ozogamicin. Corticotropin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Corticotropin. Cortisone acetate The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cortisone acetate. Corynebacterium The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin. Cyanocobalamin The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Gemtuzumab ozogamicin. Cyclopenthiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Gemtuzumab ozogamicin. Cyclophosphamide The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cyclophosphamide. Cyclosporine Gemtuzumab ozogamicin may increase the immunosuppressive activities of Cyclosporine. Cyclothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Gemtuzumab ozogamicin. Cytarabine The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cytarabine. Dabigatran The risk or severity of bleeding can be increased when Dabigatran is combined with Gemtuzumab ozogamicin. Dabigatran The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Gemtuzumab ozogamicin. Dacarbazine The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dacarbazine. Dactinomycin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dactinomycin. Dalteparin The risk or severity of bleeding can be increased when Dalteparin is combined with Gemtuzumab ozogamicin. Danaparoid The risk or severity of bleeding can be increased when Danaparoid is combined with Gemtuzumab ozogamicin. Daratumumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Daratumumab. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Gemtuzumab ozogamicin. Dasatinib The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dasatinib. Daunorubicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Daunorubicin. Decitabine The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Decitabine. Defibrotide The risk or severity of bleeding can be increased when Defibrotide is combined with Gemtuzumab ozogamicin. Deflazacort The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Deflazacort. Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Gemtuzumab ozogamicin. Desirudin The risk or severity of bleeding can be increased when Desirudin is combined with Gemtuzumab ozogamicin. Desoximetasone The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Desoximetasone. Deucravacitinib The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Deucravacitinib. Dexamethasone The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dexamethasone. Dexrazoxane The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dexrazoxane. Dextran The risk or severity of bleeding can be increased when Dextran is combined with Gemtuzumab ozogamicin. Dicoumarol The risk or severity of bleeding can be increased when Dicoumarol is combined with Gemtuzumab ozogamicin. Dienestrol Dienestrol may increase the thrombogenic activities of Gemtuzumab ozogamicin. Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Gemtuzumab ozogamicin. Difluocortolone The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Difluocortolone. Digoxin Immune The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Digoxin Immune Fab (Ovine). Dimethyl fumarate The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dimethyl fumarate. Dinutuximab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dinutuximab. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Diphenhydramine. Dipyridamole The risk or severity of bleeding can be increased when Dipyridamole is combined with Gemtuzumab ozogamicin. Diroximel The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Diroximel fumarate. Docetaxel The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Docetaxel. Dostarlimab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dostarlimab. Doxorubicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Doxorubicin. Drotrecogin alfa The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Gemtuzumab ozogamicin. Dulaglutide The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dulaglutide. Dupilumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dupilumab. Durvalumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Durvalumab. Dyclonine The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Dyclonine. Ebola Zaire The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Gemtuzumab ozogamicin. Eculizumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Eculizumab. Edetic acid The risk or severity of bleeding can be increased when Edetic acid is combined with Gemtuzumab ozogamicin. Edoxaban The risk or severity of bleeding can be increased when Edoxaban is combined with Gemtuzumab ozogamicin. Efalizumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Efalizumab. Eflapegrastim The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Eflapegrastim. Eftrenonacog alfa The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Eftrenonacog alfa. Elotuzumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Elotuzumab. Emapalumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Emapalumab. Emicizumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Emicizumab. Enoxaparin The risk or severity of bleeding can be increased when Enoxaparin is combined with Gemtuzumab ozogamicin. Epirubicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Epirubicin. Epoprostenol The risk or severity of bleeding can be increased when Epoprostenol is combined with Gemtuzumab ozogamicin. Eptifibatide The risk or severity of bleeding can be increased when Eptifibatide is combined with Gemtuzumab ozogamicin. Eptinezumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Eptinezumab. Erenumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Erenumab. Eribulin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Eribulin. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Gemtuzumab ozogamicin. Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Gemtuzumab ozogamicin. Estetrol Estetrol may increase the thrombogenic activities of Gemtuzumab ozogamicin. Estradiol Estradiol may increase the thrombogenic activities of Gemtuzumab ozogamicin. Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Gemtuzumab ozogamicin. Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Gemtuzumab ozogamicin. Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Gemtuzumab ozogamicin. Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Gemtuzumab ozogamicin. Estramustine The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Estramustine. Estriol Estriol may increase the thrombogenic activities of Gemtuzumab ozogamicin. Estrone Estrone may increase the thrombogenic activities of Gemtuzumab ozogamicin. Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Gemtuzumab ozogamicin. Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Gemtuzumab ozogamicin. Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Gemtuzumab ozogamicin. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Etidocaine. Etoposide The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Etoposide. Everolimus The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Everolimus. Evolocumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Evolocumab. Famtozinameran The therapeutic efficacy of Famtozinameran can be decreased when used in combination with Gemtuzumab ozogamicin. Fanolesomab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fanolesomab. Filgotinib The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Filgotinib. Fingolimod Gemtuzumab ozogamicin may increase the immunosuppressive activities of Fingolimod. Floxuridine The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Floxuridine. Flucytosine The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Flucytosine. Fludarabine The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fludarabine. Fludrocortisone The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fludrocortisone. Fluindione The risk or severity of bleeding can be increased when Fluindione is combined with Gemtuzumab ozogamicin. Flunisolide The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Flunisolide. Fluocinolone The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluocinolone acetonide. Fluocinonide The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluocinonide. Fluocortolone The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluocortolone. Fluorometholone The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluorometholone. Fluorouracil The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluorouracil. Flupentixol The risk or severity of myelosuppression can be increased when Flupentixol is combined with Gemtuzumab ozogamicin. Fluprednisolone The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluprednisolone. Fluticasone The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluticasone. Fluticasone furoate The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluticasone furoate. Fluticasone The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluticasone propionate. Fondaparinux The risk or severity of bleeding can be increased when Fondaparinux is combined with Gemtuzumab ozogamicin. Fremanezumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fremanezumab. Galcanezumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Galcanezumab. Gallium nitrate The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Gallium nitrate. Gemcitabine The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Gemcitabine. Glatiramer The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Glatiramer. Golimumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Golimumab. Guselkumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Guselkumab. Haemophilus The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Gemtuzumab ozogamicin. Heparin The risk or severity of bleeding can be increased when Heparin is combined with Gemtuzumab ozogamicin. Hepatitis A The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Gemtuzumab ozogamicin. Hepatitis globulin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Hepatitis B immune globulin. Hepatitis B Vaccine The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Gemtuzumab ozogamicin. Human adenovirus The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Gemtuzumab ozogamicin. Human globulin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Human cytomegalovirus immune globulin. immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Gemtuzumab ozogamicin. immune globulin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Human Rho(D) immune globulin. Human varicella The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Human varicella-zoster immune globulin. Hydrochlorothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Gemtuzumab ozogamicin. Hydrocortisone The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Hydrocortisone acetate. Hydrocortisone The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Hydrocortisone butyrate. Hydrocortisone The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Hydrocortisone succinate. Hydroflumethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Gemtuzumab ozogamicin. Hydroxychloroquine The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Hydroxychloroquine. Hydroxyurea The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Hydroxyurea. Ibalizumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ibalizumab. Ibritumomab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ibritumomab tiuxetan. Ibrutinib The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ibrutinib. Icosapent ethyl The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Gemtuzumab ozogamicin. Idarubicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Idarubicin. Idarucizumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Idarucizumab. Idelalisib The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Idelalisib. Ifosfamide The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ifosfamide. Iloprost The risk or severity of bleeding can be increased when Iloprost is combined with Gemtuzumab ozogamicin. Imatinib The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Imatinib. Imdevimab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Imdevimab. Imlifidase The therapeutic efficacy of Gemtuzumab ozogamicin can be decreased when used in combination with Imlifidase. Indomethacin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Indomethacin. Inebilizumab The risk or severity of infection can be increased when Gemtuzumab ozogamicin is combined with Inebilizumab. Infliximab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Infliximab. Influenza A The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin. Influenza A virus The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin. Influenza The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Gemtuzumab ozogamicin. Influenza A virus The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin. Influenza A virus A The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin. Influenza A The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Gemtuzumab ozogamicin. Influenza A The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin. Influenza A virus The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin. Influenza A The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin. Influenza B The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin. Influenza B The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin. Influenza B The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin. Influenza B The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin. Inotuzumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Inotuzumab ozogamicin. Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Gemtuzumab ozogamicin. Interferon alfa-2b The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Interferon alfa-2b. Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Gemtuzumab ozogamicin. Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Gemtuzumab ozogamicin. Interferon The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Interferon alfacon-1. Interferon beta-1b The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Interferon beta-1b. Interferon gamm The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Gemtuzumab ozogamicin. Ipilimumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ipilimumab. Irinotecan The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Irinotecan. Isatuximab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Isatuximab. Ixabepilone The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ixabepilone. Ixekizumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ixekizumab. COVID-19 Vaccine The therapeutic efficacy of Janssen COVID-19 Vaccine can be decreased when used in combination with Gemtuzumab ozogamicin. Ja encephalitis The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin. Lanadelumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lanadelumab. Leflunomide The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Leflunomide. Lenalidomide The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lenalidomide. Lepirudin The risk or severity of bleeding can be increased when Lepirudin is combined with Gemtuzumab ozogamicin. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Levobupivacaine. Lidocaine The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Lidocaine. Linezolid The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Linezolid. Lipegfilgrastim Gemtuzumab ozogamicin may increase the myelosuppressive activities of Lipegfilgrastim. Lomustine The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lomustine. Loncastuximab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Loncastuximab tesirine. Lopinavir The serum concentration of Gemtuzumab ozogamicin can be increased when it is combined with Lopinavir. Maftivimab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Maftivimab. Magnesium The serum concentration of Magnesium can be decreased when it is combined with Gemtuzumab ozogamicin. Margetuximab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Margetuximab. Measles virus The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Gemtuzumab ozogamicin. Mechlorethamine The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mechlorethamine. Meloxicam The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Meloxicam. Melphalan The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Melphalan. Meningococcal The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Gemtuzumab ozogamicin. Mepivacaine The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Mepivacaine. Mepolizumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mepolizumab. Meprednisone The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Meprednisone. Mercaptopurine The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mercaptopurine. Mestranol Mestranol may increase the thrombogenic activities of Gemtuzumab ozogamicin. Methimazole The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Methimazole. Methotrexate The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Methotrexate. Methoxy The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Gemtuzumab ozogamicin. Methylprednisolone The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Methylprednisolone. Mirvetuximab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mirvetuximab Soravtansine. Mitomycin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mitomycin. Mitoxantrone The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mitoxantrone. COVID-19 Vaccine The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Gemtuzumab ozogamicin. Modified v The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Gemtuzumab ozogamicin. Mogamulizumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mogamulizumab. Mometasone The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mometasone furoate. Monomethyl The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Monomethyl fumarate. Mosunetuzumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mosunetuzumab. Mumps virus n The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Gemtuzumab ozogamicin. Muromonab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Muromonab. Mycophenolate The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mycophenolate mofetil. Mycophenolic The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mycophenolic acid. Nadroparin The risk or severity of bleeding can be increased when Nadroparin is combined with Gemtuzumab ozogamicin. Natalizumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Natalizumab. Necitumumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Necitumumab. Nelarabine The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Nelarabine. Nilotinib The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Nilotinib. Nimesulide The risk or severity of bleeding can be increased when Nimesulide is combined with Gemtuzumab ozogamicin. Nivolumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Nivolumab. Nuvaxovid The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Gemtuzumab ozogamicin. Obiltoxaximab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Obiltoxaximab. Obinutuzumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Obinutuzumab. Ocrelizumab Ocrelizumab may increase the immunosuppressive activities of Gemtuzumab ozogamicin. Odesivimab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Odesivimab. Ofatumumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ofatumumab. Olaparib The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Olaparib. Olaratumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Olaratumab. Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Gemtuzumab ozogamicin. Oxaliplatin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Oxaliplatin. Oxetacaine The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Oxetacaine. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Oxybuprocaine. Ozanimod The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ozanimod. Paclitaxel The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Paclitaxel. Palbociclib The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Palbociclib. Palifermin The therapeutic efficacy of Palifermin can be decreased when used in combination with Gemtuzumab ozogamicin. Palivizumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Palivizumab. Panitumumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Panitumumab. Panobinostat The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Panobinostat. Parnaparin The risk or severity of bleeding can be increased when Parnaparin is combined with Gemtuzumab ozogamicin. Pazopanib The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pazopanib. Pegaspargase The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pegaspargase. Pegcetacoplan The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pegcetacoplan. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Gemtuzumab ozogamicin. Peginterferon The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Gemtuzumab ozogamicin. Peginterferon 2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Gemtuzumab ozogamicin. Peginterferon The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Peginterferon beta-1a. Pembrolizumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pembrolizumab. Pemetrexed The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pemetrexed. Penicillamine The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Penicillamine. Pentosan p The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Gemtuzumab ozogamicin. Pentostatin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pentostatin. Pentoxifylline The risk or severity of bleeding can be increased when Pentoxifylline is combined with Gemtuzumab ozogamicin. Pertussis vaccine The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Gemtuzumab ozogamicin. Pertuzumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pertuzumab. Pexidartinib Gemtuzumab ozogamicin may increase the hepatotoxic activities of Pexidartinib. Phenindione The risk or severity of bleeding can be increased when Phenindione is combined with Gemtuzumab ozogamicin. Phenol The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Phenol. Phenprocoumon The risk or severity of bleeding can be increased when Phenprocoumon is combined with Gemtuzumab ozogamicin. Phenylalanine The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Phenylalanine. Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Gemtuzumab ozogamicin. Pirfenidone The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pirfenidone. Polatuzumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Polatuzumab vedotin. Polyestradiol Polyestradiol phosphate may increase the thrombogenic activities of Gemtuzumab ozogamicin. Polythiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Gemtuzumab ozogamicin. Pomalidomide The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pomalidomide. Ponatinib The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ponatinib. Ponesimod The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ponesimod. Pralatrexate The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pralatrexate. Pramocaine The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Pramocaine. Prasugrel The risk or severity of bleeding can be increased when Prasugrel is combined with Gemtuzumab ozogamicin. Prednisolone The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Prednisolone. Prednisone The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Prednisone. Prilocaine The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Prilocaine. Procaine The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Procaine. Procarbazine The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Procarbazine. Proparacaine The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Proparacaine. Propoxycaine The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Propoxycaine. Propylthiouracil The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Propylthiouracil. Protein C The risk or severity of bleeding can be increased when Protein C is combined with Gemtuzumab ozogamicin. Protein S The risk or severity of bleeding can be increased when Protein S human is combined with Gemtuzumab ozogamicin. Quinestrol Quinestrol may increase the thrombogenic activities of Gemtuzumab ozogamicin. Ramucirumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ramucirumab. Ranibizumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ranibizumab. Ravulizumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ravulizumab. Raxibacumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Raxibacumab. Reslizumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Reslizumab. Reteplase The risk or severity of bleeding can be increased when Reteplase is combined with Gemtuzumab ozogamicin. Reviparin The risk or severity of bleeding can be increased when Reviparin is combined with Gemtuzumab ozogamicin. Rilonacept The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Rilonacept. Risankizumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Risankizumab. Rituximab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Rituximab. Rivaroxaban The risk or severity of bleeding can be increased when Rivaroxaban is combined with Gemtuzumab ozogamicin. Roflumilast Roflumilast may increase the immunosuppressive activities of Gemtuzumab ozogamicin. Romosozumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Romosozumab. Ropeginterferon The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ropeginterferon alfa-2b. Ropivacaine The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Ropivacaine. Rotavirus vaccine The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Gemtuzumab ozogamicin. Rubella virus vaccine The risk or severity of infection can be increased when Rubella virus vaccine is combined with Gemtuzumab ozogamicin. Ruxolitinib The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ruxolitinib. Sacituzumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sacituzumab govitecan. Sarilumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sarilumab. Satralizumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Satralizumab. Secukinumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Secukinumab. Siltuximab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Siltuximab. Siponimod The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Siponimod. Sipuleucel-T The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Gemtuzumab ozogamicin. Sirolimus The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sirolimus. Smallpox The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Gemtuzumab ozogamicin. Sodium citrate The risk or severity of bleeding can be increased when Sodium citrate is combined with Gemtuzumab ozogamicin. Sorafenib The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sorafenib. Sotrovimab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sotrovimab. Spesolimab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Spesolimab. Streptokinase The risk or severity of bleeding can be increased when Streptokinase is combined with Gemtuzumab ozogamicin. Streptozocin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Streptozocin. Sulesomab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sulesomab. Sulfamethoxazole The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Gemtuzumab ozogamicin. Sulfasalazine The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sulfasalazine. Sulfinpyrazone The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Gemtuzumab ozogamicin. Sulodexide The risk or severity of bleeding can be increased when Sulodexide is combined with Gemtuzumab ozogamicin. Sunitinib The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sunitinib. Sutimlimab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sutimlimab. SyEstrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Gemtuzumab ozogamicin. SEstrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Gemtuzumab ozogamicin. Tacrolimus Tacrolimus may increase the immunosuppressive activities of Gemtuzumab ozogamicin. Tafasitamab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tafasitamab. Tedizolid The risk or severity of myelosuppression can be increased when Gemtuzumab ozogamicin is combined with Tedizolid phosphate. Temozolomide The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Temozolomide. Temsirolimus The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Temsirolimus. Tenecteplase The risk or severity of bleeding can be increased when Tenecteplase is combined with Gemtuzumab ozogamicin. Teniposide The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Teniposide. Teplizumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Teplizumab. Teprotumumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Teprotumumab. Teriflunomide The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Teriflunomide. Tetanus The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tetanus immune globulin, human. Tetracaine The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Tetracaine. Tezepelumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tezepelumab. Thalidomide The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Thalidomide. Thiotepa The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Thiotepa. Tibolone Tibolone may increase the thrombogenic activities of Gemtuzumab ozogamicin. Ticagrelor The risk or severity of bleeding can be increased when Ticagrelor is combined with Gemtuzumab ozogamicin. Tick-borne The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin. Ticlopidine The risk or severity of bleeding can be increased when Ticlopidine is combined with Gemtuzumab ozogamicin. Tildrakizumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tildrakizumab. Tinzaparin The risk or severity of bleeding can be increased when Tinzaparin is combined with Gemtuzumab ozogamicin. Tioguanine The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tioguanine. Tirofiban The risk or severity of bleeding can be increased when Tirofiban is combined with Gemtuzumab ozogamicin. Tisotumab vedotin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tisotumab vedotin. Tixagevimab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tixagevimab. Tixocortol The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tixocortol. Tocilizumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tocilizumab. Tofacitinib Gemtuzumab ozogamicin may increase the immunosuppressive activities of Tofacitinib. Topotecan The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Topotecan. Tositumomab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tositumomab. Trabectedin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Trabectedin. Tralokinumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tralokinumab. Trastuzumab Trastuzumab may increase the neutropenic activities of Gemtuzumab ozogamicin. Trastuzumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Trastuzumab deruxtecan. Trastuzumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Trastuzumab emtansine. Tremelimumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tremelimumab. Tretinoin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tretinoin. Triamcinolone The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Triamcinolone. Trichlormethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Gemtuzumab ozogamicin. Trifluridine The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Trifluridine. Triflusal The risk or severity of bleeding can be increased when Triflusal is combined with Gemtuzumab ozogamicin. Trilostane The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Trilostane. Typhoid vaccine The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Gemtuzumab ozogamicin. Typhoid Vaccine The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Gemtuzumab ozogamicin. Typhoid The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Gemtuzumab ozogamicin. Upadacitinib The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Upadacitinib. Urokinase The risk or severity of bleeding can be increased when Urokinase is combined with Gemtuzumab ozogamicin. Ustekinumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ustekinumab. Valoctocogene The therapeutic efficacy of Valoctocogene roxaparvovec can be decreased when used in combination with Gemtuzumab ozogamicin. Varicella zoster The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Gemtuzumab ozogamicin. Varicella zoster The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Gemtuzumab ozogamicin. Vedolizumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vedolizumab. Vibrio cholerae The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Gemtuzumab ozogamicin. Vilanterol The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vilanterol. Vinblastine The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vinblastine. Vincristine The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vincristine. Vindesine The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vindesine. Vinorelbine The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vinorelbine. Voclosporin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Voclosporin. Vorapaxar The risk or severity of bleeding can be increased when Vorapaxar is combined with Gemtuzumab ozogamicin. Vorinostat The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vorinostat. Warfarin The risk or severity of bleeding can be increased when Warfarin is combined with Gemtuzumab ozogamicin. Ximelagatran The risk or severity of bleeding can be increased when Ximelagatran is combined with Gemtuzumab ozogamicin. Yellow fever The risk or severity of infection can be increased when Yellow fever vaccine is combined with Gemtuzumab ozogamicin. Zidovudine The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Zidovudine. Pregnancy and Lactation US FDA pregnancy category Not Assigned Pregnancy Based on its mechanism of action and findings from animal studies [see Clinical Pharmacology (12.1) and Nonclinical Toxicology (13.1)], MYLOTARG can cause embryo-fetal harm when administered to a pregnant woman. There are no available data on MYLOTARG use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. In rat embryo-fetal development studies, gemtuzumab ozogamicin caused embryo-fetal toxicity at maternal systemic exposures that were greater than or equal to 0.4 times the exposure in patients at the maximum recommended dose, based on AUC (see Data). If MYLOTARG is used during pregnancy, or if the patient becomes pregnant while taking MYLOTARG, advise the patient of the potential risk to a fetus. Lactation There are no data on the presence of gemtuzumab ozogamicin or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production. Because of the potential for adverse reactions in breastfed infants, women should not breastfeed during treatment with MYLOTARG and for at least 1 month after the final dose. How should this medicine be used? Gemtuzumab ozogamicin injection comes as a powder to be mixed with liquid and given through a needle or catheter placed into a vein. It is usually injected slowly over a period of 2 hours. Your doctor will tell you how often you will receive gemtuzumab ozogamicin injection. The dosing schedule depends on if you are being treated with other chemotherapy medications, if your cancer was previously treated, and how your body responds to the medication. Gemtuzumab ozogamicin injection may cause serious or life-threatening reactions during an infusion and for up to a day afterwards. You will receive certain medications to help prevent a reaction before you receive each dose of gemtuzumab ozogamicin. A doctor or nurse will watch you closely while you are receiving the infusion and shortly after the infusion to be sure you are not having a serious reaction to the medication. Tell your doctor or nurse immediately if you experience any of the following symptoms that may occur during or within 24 hours after the infusion: rash, fever, chills, fast heartbeat, swollen tongue or throat, shortness of breath or difficulty breathing. Your doctor may slow down your infusion, delay, or stop your treatment with gemtuzumab ozogamicin injection, or treat you with additional medications depending on your response to the medication and any side effects that you experience. Talk to your doctor about how you are feeling during and after your treatment. What special precautions should I follow? Before receiving gemtuzumab ozogamicin injection, tell your doctor and pharmacist if you are allergic to gemtuzumab ozogamicin, any other medications, or any of the ingredients in gemtuzumab ozogamicin injection. Ask your pharmacist for a list of the ingredients. tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: amiodarone (Cordarone, Nexterone, Pacerone), anagrelide (Agrylin), chloroquine, chlorpromazine, cilostazol, citalopram (Celexa), disopyramide (Norpace), dofetilide (Tikosyn), donepezil (Aricept, in Namzaric), dronedarone (Multaq), escitalopram (Lexapro), flecainide (Tambocor), fluconazole (Diflucan), haloperidol (Haldol), ibutilide (Corvert), methadone (Methadose, Dolophine), ondansetron (Zuplenz, Sofran), pimozide (Orap), procainamide, quinidine (in Nuedexta), sotalol (Betapace, Sorine, Sotylize), and thioridazine. Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with gemtuzumab ozogamicin injection, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list. tell your doctor if you or anyone in your family has or has ever had long QT syndrome (condition that increases the risk of developing an irregular heartbeat that may cause fainting or sudden death), or if you have or have ever had or higher or lower than normal levels of sodium, potassium, calcium, or magnesium in your blood. tell your doctor if you are pregnant, plan to become pregnant, or plan to father a child. You should not become pregnant while you are receiving gemtuzumab ozogamicin injection. You will need to have a negative pregnancy test before you begin receiving this medication. Use effective birth control during your treatment with gemtuzumab ozogamicin injection and for 6 months after your final dose. If you are a male and your partner can become pregnant, you should use effective birth control during your treatment and for 3 months after your final dose. If you or your partner become pregnant while receiving gemtuzumab ozogamicin injection, call your doctor. tell your doctor if you are breastfeeding. You should not breastfeed while you are receiving gemtuzumab ozogamicin injection, and for 1 month after your final dose. you should know that this medication may decrease fertility in men and women. Talk to your doctor about the risks of receiving gemtuzumab ozogamicin. References https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761060lbl.pdf https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-gemtuzumab-ozogamicin-cd33-positive-aml-pediatric-patients https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761060s004lbl.pdf https://pubchem.ncbi.nlm.nih.gov/substance/178103381 https://go.drugbank.com/drugs/DB00056 https://medlineplus.gov/druginfo/meds/a618005.html https://www.drugs.com/pregnancy/gemtuzumab.html https://en.wikipedia.org/wiki/Gemtuzumab_ozogamicin https://www.mayoclinic.org/drugs-supplements/gemtuzumab-intravenous-route/side-effects/drg-20406532 https://www.webmd.com/drugs/2/drug-19457/gemtuzumab-ozogamicin-intravenous/details/list-contraindications Show More